A multicenter analysis of elvitegravir use during pregnancy on HIV viral suppression and perinatal outcomes

Martina L. Badell; Anandi N. Sheth; Florence Momplaisir; Lisa Rahangdale; Jo Nell Potter; Padmashree C. Woodham; Gweneth B. Lazenby; William R. Short; Scott E. Gillespie; Nevert Baldreldin; Emily S. Miller; Gregg Alleyne; Lunthita M. Duthely; Stephanie M. Allen; Judy Levison; Rana Chakraborty

doi:10.1093/ofid/ofz129

A multicenter analysis of elvitegravir use during pregnancy on HIV viral suppression and perinatal outcomes

Martina L. Badell, Anandi N. Sheth, Florence Momplaisir, Lisa Rahangdale, Jo Nell Potter, Padmashree C. Woodham, Gweneth B. Lazenby, William R. Short, Scott E. Gillespie, Nevert Baldreldin, Emily S. Miller, Gregg Alleyne, Lunthita M. Duthely, Stephanie M. Allen, Judy Levison, Rana Chakraborty

Research output: Contribution to journal › Article › peer-review

8 Scopus citations

Abstract

Background. There is a knowledge gap on the clinical use of elvitegravir (EVG) during pregnancy and maternal viral suppression. Our objective was to evaluate the effects of EVG use in pregnancy on rates of HIV virologic suppression and perinatal outcomes. Methods. We conducted a retrospective, multicenter study of pregnant women living with HIV (WLHIV) who used EVGcontaining antiretroviral therapy (ART) between January 2014 and March 2017 at 9 tertiary care centers in the United States. WLHIV were included if they took EVG at any time during pregnancy. We described the characteristics of the WLHIV using EVG during the study period and evaluated the rates of HIV suppression and perinatal outcomes. Results. Among 134 pregnant WLHIV who received EVG at any time during pregnancy, viral suppression at delivery (HIV-1 RNA < 40 copies/mL) occurred in 81.3%. In WLHIV who initiated EVG before pregnancy and continued through delivery (n = 68), the rate of viral suppression at delivery was 88.2%. The average gestational age at the time of delivery was 37 weeks 6 days, and the overall rate of preterm birth was 20%. No cases of open neural tube defects were noted in women on EVG at the time of conception (n = 82). The perinatal HIV transmission rate was 0.8%. Conclusions. EVG use was associated with high sustained levels of HIV suppression during pregnancy and a low rate of perinatal HIV transmission.

Original language	English (US)
Journal	Open Forum Infectious Diseases
Volume	6
Issue number	4
DOIs	https://doi.org/10.1093/ofid/ofz129
State	Published - Apr 2019
Externally published	Yes

Keywords

HIV viral suppression
Obstetrics and gynecology
Perinatal outcomes
Prevention of mother-to-child transmission

ASJC Scopus subject areas

Infectious Diseases
Oncology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1093/ofid/ofz129

Cite this

Badell, M. L., Sheth, A. N., Momplaisir, F., Rahangdale, L., Potter, J. N., Woodham, P. C., Lazenby, G. B., Short, W. R., Gillespie, S. E., Baldreldin, N., Miller, E. S., Alleyne, G., Duthely, L. M., Allen, S. M., Levison, J., & Chakraborty, R. (2019). A multicenter analysis of elvitegravir use during pregnancy on HIV viral suppression and perinatal outcomes. Open Forum Infectious Diseases, 6(4). https://doi.org/10.1093/ofid/ofz129

Badell, ML, Sheth, AN, Momplaisir, F, Rahangdale, L, Potter, JN, Woodham, PC, Lazenby, GB, Short, WR, Gillespie, SE, Baldreldin, N, Miller, ES, Alleyne, G, Duthely, LM, Allen, SM, Levison, J & Chakraborty, R 2019, 'A multicenter analysis of elvitegravir use during pregnancy on HIV viral suppression and perinatal outcomes', Open Forum Infectious Diseases, vol. 6, no. 4. https://doi.org/10.1093/ofid/ofz129

@article{352b2699ac85402281d2933db4a874d2,

title = "A multicenter analysis of elvitegravir use during pregnancy on HIV viral suppression and perinatal outcomes",

abstract = "Background. There is a knowledge gap on the clinical use of elvitegravir (EVG) during pregnancy and maternal viral suppression. Our objective was to evaluate the effects of EVG use in pregnancy on rates of HIV virologic suppression and perinatal outcomes. Methods. We conducted a retrospective, multicenter study of pregnant women living with HIV (WLHIV) who used EVGcontaining antiretroviral therapy (ART) between January 2014 and March 2017 at 9 tertiary care centers in the United States. WLHIV were included if they took EVG at any time during pregnancy. We described the characteristics of the WLHIV using EVG during the study period and evaluated the rates of HIV suppression and perinatal outcomes. Results. Among 134 pregnant WLHIV who received EVG at any time during pregnancy, viral suppression at delivery (HIV-1 RNA < 40 copies/mL) occurred in 81.3%. In WLHIV who initiated EVG before pregnancy and continued through delivery (n = 68), the rate of viral suppression at delivery was 88.2%. The average gestational age at the time of delivery was 37 weeks 6 days, and the overall rate of preterm birth was 20%. No cases of open neural tube defects were noted in women on EVG at the time of conception (n = 82). The perinatal HIV transmission rate was 0.8%. Conclusions. EVG use was associated with high sustained levels of HIV suppression during pregnancy and a low rate of perinatal HIV transmission.",

keywords = "HIV viral suppression, Obstetrics and gynecology, Perinatal outcomes, Prevention of mother-to-child transmission",

author = "Badell, {Martina L.} and Sheth, {Anandi N.} and Florence Momplaisir and Lisa Rahangdale and Potter, {Jo Nell} and Woodham, {Padmashree C.} and Lazenby, {Gweneth B.} and Short, {William R.} and Gillespie, {Scott E.} and Nevert Baldreldin and Miller, {Emily S.} and Gregg Alleyne and Duthely, {Lunthita M.} and Allen, {Stephanie M.} and Judy Levison and Rana Chakraborty",

note = "Publisher Copyright: {\textcopyright} The Author(s) 2019.",

year = "2019",

month = apr,

doi = "10.1093/ofid/ofz129",

language = "English (US)",

volume = "6",

journal = "Open Forum Infectious Diseases",

issn = "2328-8957",

publisher = "Oxford University Press",

number = "4",

}

TY - JOUR

T1 - A multicenter analysis of elvitegravir use during pregnancy on HIV viral suppression and perinatal outcomes

AU - Badell, Martina L.

AU - Sheth, Anandi N.

AU - Momplaisir, Florence

AU - Rahangdale, Lisa

AU - Potter, Jo Nell

AU - Woodham, Padmashree C.

AU - Lazenby, Gweneth B.

AU - Short, William R.

AU - Gillespie, Scott E.

AU - Baldreldin, Nevert

AU - Miller, Emily S.

AU - Alleyne, Gregg

AU - Duthely, Lunthita M.

AU - Allen, Stephanie M.

AU - Levison, Judy

AU - Chakraborty, Rana

PY - 2019/4

Y1 - 2019/4

N2 - Background. There is a knowledge gap on the clinical use of elvitegravir (EVG) during pregnancy and maternal viral suppression. Our objective was to evaluate the effects of EVG use in pregnancy on rates of HIV virologic suppression and perinatal outcomes. Methods. We conducted a retrospective, multicenter study of pregnant women living with HIV (WLHIV) who used EVGcontaining antiretroviral therapy (ART) between January 2014 and March 2017 at 9 tertiary care centers in the United States. WLHIV were included if they took EVG at any time during pregnancy. We described the characteristics of the WLHIV using EVG during the study period and evaluated the rates of HIV suppression and perinatal outcomes. Results. Among 134 pregnant WLHIV who received EVG at any time during pregnancy, viral suppression at delivery (HIV-1 RNA < 40 copies/mL) occurred in 81.3%. In WLHIV who initiated EVG before pregnancy and continued through delivery (n = 68), the rate of viral suppression at delivery was 88.2%. The average gestational age at the time of delivery was 37 weeks 6 days, and the overall rate of preterm birth was 20%. No cases of open neural tube defects were noted in women on EVG at the time of conception (n = 82). The perinatal HIV transmission rate was 0.8%. Conclusions. EVG use was associated with high sustained levels of HIV suppression during pregnancy and a low rate of perinatal HIV transmission.

AB - Background. There is a knowledge gap on the clinical use of elvitegravir (EVG) during pregnancy and maternal viral suppression. Our objective was to evaluate the effects of EVG use in pregnancy on rates of HIV virologic suppression and perinatal outcomes. Methods. We conducted a retrospective, multicenter study of pregnant women living with HIV (WLHIV) who used EVGcontaining antiretroviral therapy (ART) between January 2014 and March 2017 at 9 tertiary care centers in the United States. WLHIV were included if they took EVG at any time during pregnancy. We described the characteristics of the WLHIV using EVG during the study period and evaluated the rates of HIV suppression and perinatal outcomes. Results. Among 134 pregnant WLHIV who received EVG at any time during pregnancy, viral suppression at delivery (HIV-1 RNA < 40 copies/mL) occurred in 81.3%. In WLHIV who initiated EVG before pregnancy and continued through delivery (n = 68), the rate of viral suppression at delivery was 88.2%. The average gestational age at the time of delivery was 37 weeks 6 days, and the overall rate of preterm birth was 20%. No cases of open neural tube defects were noted in women on EVG at the time of conception (n = 82). The perinatal HIV transmission rate was 0.8%. Conclusions. EVG use was associated with high sustained levels of HIV suppression during pregnancy and a low rate of perinatal HIV transmission.

KW - HIV viral suppression

KW - Obstetrics and gynecology

KW - Perinatal outcomes

KW - Prevention of mother-to-child transmission

UR - http://www.scopus.com/inward/record.url?scp=85066398920&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85066398920&partnerID=8YFLogxK

U2 - 10.1093/ofid/ofz129

DO - 10.1093/ofid/ofz129

M3 - Article

AN - SCOPUS:85066398920

SN - 2328-8957

VL - 6

JO - Open Forum Infectious Diseases

JF - Open Forum Infectious Diseases

IS - 4

ER -

A multicenter analysis of elvitegravir use during pregnancy on HIV viral suppression and perinatal outcomes

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this